Salivary tumor necrosis factor-? and interleukin-6 in patients with head and neck cancer before and after radiotherapy
Abstract
Mohammed H. Alburgaiba, Fawaz D. Al-Aswad, Haider N. Salh
Head and neck cancer (HNC) means a heterogeneous group of cancers in multiple sites of head and neck structures, including oral and nasal cavity, paranasal sinuses, larynx, pharynx and salivary glands. Radiotherapy (RT) is one of the fundamental treatment options for malignancy and widely used as HNC treatment strategy. Salivary cytokines such as tumor necrosis factorα (TNF-α) and interleukin-6 (IL-6) have wide biological activities like regulating inflammatory and immunological events. Aim of the study is to assess the level of salivary TNF-α and IL-6 in HNC patients before and after two techniques of head and neck radiotherapy. The study included thirty healthy individuals as control group and two patients’ groups with HNC: the first group consist of 30 patients treated by three-dimensional conformal radiation therapy (3DCRT) and the second group also consist of the same patient's number but treated by intensity-modulated radiation therapy (IMRT). The level of both cytokines are significantly higher in patients before RT than in control group. The study shows significant elevation in levels of salivary TNF-α and IL-6 after finishing RT. The salivary IL-6 and TNF-α are high in patients with HNC than in healthy individuals, so they can be used as biomarkers for early detection of HNC.
| How to Cite this Article |
| Pubmed Style Mohammed H. Alburgaiba, Fawaz D. Al-Aswad, Haider N. Salh. Salivary tumor necrosis factor-α and interleukin-6 in patients with head and neck cancer before and after radiotherapy. SRP. 2019; 10(1): 146-150. doi:10.5530/srp.2019.1.27 Web Style Mohammed H. Alburgaiba, Fawaz D. Al-Aswad, Haider N. Salh. Salivary tumor necrosis factor-α and interleukin-6 in patients with head and neck cancer before and after radiotherapy. http://www.sysrevpharm.org/?mno=302644729 [Access: March 29, 2021]. doi:10.5530/srp.2019.1.27 AMA (American Medical Association) Style Mohammed H. Alburgaiba, Fawaz D. Al-Aswad, Haider N. Salh. Salivary tumor necrosis factor-α and interleukin-6 in patients with head and neck cancer before and after radiotherapy. SRP. 2019; 10(1): 146-150. doi:10.5530/srp.2019.1.27 Vancouver/ICMJE Style Mohammed H. Alburgaiba, Fawaz D. Al-Aswad, Haider N. Salh. Salivary tumor necrosis factor-α and interleukin-6 in patients with head and neck cancer before and after radiotherapy. SRP. (2019), [cited March 29, 2021]; 10(1): 146-150. doi:10.5530/srp.2019.1.27 Harvard Style Mohammed H. Alburgaiba, Fawaz D. Al-Aswad, Haider N. Salh (2019) Salivary tumor necrosis factor-α and interleukin-6 in patients with head and neck cancer before and after radiotherapy. SRP, 10 (1), 146-150. doi:10.5530/srp.2019.1.27 Turabian Style Mohammed H. Alburgaiba, Fawaz D. Al-Aswad, Haider N. Salh. 2019. Salivary tumor necrosis factor-α and interleukin-6 in patients with head and neck cancer before and after radiotherapy. Systematic Reviews in Pharmacy, 10 (1), 146-150. doi:10.5530/srp.2019.1.27 Chicago Style Mohammed H. Alburgaiba, Fawaz D. Al-Aswad, Haider N. Salh. "Salivary tumor necrosis factor-α and interleukin-6 in patients with head and neck cancer before and after radiotherapy." Systematic Reviews in Pharmacy 10 (2019), 146-150. doi:10.5530/srp.2019.1.27 MLA (The Modern Language Association) Style Mohammed H. Alburgaiba, Fawaz D. Al-Aswad, Haider N. Salh. "Salivary tumor necrosis factor-α and interleukin-6 in patients with head and neck cancer before and after radiotherapy." Systematic Reviews in Pharmacy 10.1 (2019), 146-150. Print. doi:10.5530/srp.2019.1.27 APA (American Psychological Association) Style Mohammed H. Alburgaiba, Fawaz D. Al-Aswad, Haider N. Salh (2019) Salivary tumor necrosis factor-α and interleukin-6 in patients with head and neck cancer before and after radiotherapy. Systematic Reviews in Pharmacy, 10 (1), 146-150. doi:10.5530/srp.2019.1.27 |
Abstract
PDF
How to cite this article
Related Records